Paid Clinical Trials Shreveport

Discover 162 paid clinical trials in Shreveport, Louisiana. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 162

Chemotherapy with Endocrine TherapyEvaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Shreveport LA, Little Rock AR, Conroe TX, Fort Smith ARshow 715 more

Code:

NCT05879926

Conditions

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Ovarian Function Suppression + Aromatase Inhibitor

Adjuvant Chemotherapy + Ovarian Function Suppression

Lenalidomide & DaratumumabS1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Recruiting

PHASE3

Sponsor:

SWOG Cancer Research Network

Location:

Shreveport LA, Monroe LA, Hot Springs AR, Little Rock ARshow 530 more

Code:

NCT04071457

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Lenalidomide

Daratumumab/rHuPH20

CariprazineA Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

Recruiting

PHASE3

Sponsor:

AbbVie

Location:

Shreveport LA, Beaumont TX, Plano TX, Dallas TXshow 45 more

Code:

NCT04777357

Conditions

Depression

Bipolar I Disorder

Eligibility Criteria

Sex: All

Age: 10 - 17

Healthy Volunteers: Not accepted

Interventions

Cariprazine

Placebo

Observational StudyA Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

Recruiting

Sponsor:

Target PharmaSolutions, Inc.

Location:

Shreveport LA, Dallas TX, Houston TX, Houma LAshow 52 more

Code:

NCT02815891

Conditions

Nonalcoholic Fatty Liver

Nonalcoholic Steatohepatitis

Eligibility Criteria

Sex: All

Age: 2+

Healthy Volunteers: Not accepted

SaruparibSaruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

Shreveport LA, Tyler TX, Plano TX, Little Rock ARshow 115 more

Code:

NCT06120491

Conditions

Metastatic Castration-Sensitive Prostate Cancer

Eligibility Criteria

Sex: Male

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Saruparib

Placebo

Abiraterone Acetate

Darolutamide

Enzalutamide

Zanubrutinib & Anti-CD20A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Recruiting

PHASE3

Sponsor:

BeiGene

Location:

Shreveport LA, Longview TX, Tyler TX, Palestine TXshow 58 more

Code:

NCT05100862

Conditions

Relapsed/Refractory Follicular Lymphoma

Marginal Zone Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Zanubrutinib

Rituximab

Lenalidomide

Obinutuzumab

Observational StudyOptilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters

Recruiting

Sponsor:

Urotronic Inc.

Location:

Shreveport LA, Little Rock AR, Dallas TX, Tampa FLshow 5 more

Code:

NCT05383274

Conditions

Urethral Stricture

Eligibility Criteria

Sex: Male

Age: 22 - 65

Healthy Volunteers: Not accepted

Interventions

Optilume Urethral DCB

Sacituzumab Tirumotecan & PembrolizumabSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Recruiting

PHASE3

Sponsor:

Merck Sharp & Dohme LLC

Location:

Shreveport LA, Tyler TX, Monroe LA, Dallas TXshow 39 more

Code:

NCT06393374

Conditions

Triple-Negative Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pembrolizumab

Sacituzumab tirumotecan

Capecitabine

SelinexorSelinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Recruiting

PHASE3

Sponsor:

Karyopharm Therapeutics Inc

Location:

Shreveport LA, Tyler TX, Little Rock AR, Dallas TXshow 71 more

Code:

NCT05611931

Conditions

Endometrial Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Selinexor

Matching Placebo for selinexor

Sacituzumab vs. TreatmentA Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Recruiting

PHASE3

Sponsor:

Merck Sharp & Dohme LLC

Location:

Shreveport LA, Fort Worth TX, Houston TX, New Orleans LAshow 32 more

Code:

NCT06459180

Conditions

Cervical Cancer

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Sacituzumab Tirumotecan

Pemetrexed

Tisotumab Vedotin

Topotecan

Vinorelbine